Skip to content
2000
Volume 33, Issue 3
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

As research on upper tract urothelial carcinoma (UTUC) has deepened, the value of biomarkers in the prognostic evaluation of UTUC has been gradually highlighted. As a high-grade epithelial tumor derived from the renal pelvis or ureter, UTUC has a significant prognostic challenge to patients, given its high invasiveness and recurrence rate for the formation of post-operative bladder cancer. To better predict the recurrence and metastasis risk of UTUC, this article provides a comprehensive review of hematologic, urologic, genetic, and histologic biomarker studies on the prognostic assessment of UTUC. This study covers a broad range of different kinds of biomarkers, as shown in the graphical abstract. By systematically analyzing these biomarkers, we will have a better understanding of the biological features of UTUC, and it will provide more comprehensive and accurate information for its prognostic assessment. This will not only help clinicians develop more precise treatment strategies, but also provide patients with more personalized rehabilitation recommendations.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673339558250123110322
2025-02-07
2026-03-11

  • From This Site

    /content/journals/cmc/10.2174/0109298673339558250123110322
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SiegelR.L. MillerK.D. FuchsH.E. JemalA. Cancer statistics, 2021.CA Cancer J. Clin.202171173310.3322/caac.2165433433946
     [Google Scholar]
  2. LughezzaniG. BurgerM. MargulisV. MatinS.F. NovaraG. RoupretM. ShariatS.F. WoodC.G. ZigeunerR. Prognostic factors in upper urinary tract urothelial carcinomas: A comprehensive review of the current literature.Eur. Urol.201262110011410.1016/j.eururo.2012.02.03022381168
     [Google Scholar]
  3. RouprêtM. SeisenT. BirtleA.J. CapounO. CompératE.M. EscrigD.J.L. AnderssonG.I. LiedbergF. MariappanP. MostafidH.A. PradereB. RhijnV.B.W.G. ShariatS.F. RaiB.P. SoriaF. SoukupV. WoodR.G. XylinasE.N. LecomteM.A. GonteroP. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update.Eur. Urol.2023841496410.1016/j.eururo.2023.03.01336967359
     [Google Scholar]
  4. RamanJ.D. MesserJ. SielatyckiJ.A. HollenbeakC.S. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005.BJU Int.201110771059106410.1111/j.1464‑410X.2010.09675.x20825397
     [Google Scholar]
  5. RamanJ.D. ScherrD.S. Management of patients with upper urinary tract transitional cell carcinoma.Nat. Clin. Pract. Urol.20074843244310.1038/ncpuro087517673914
     [Google Scholar]
  6. KrajewskiW. ŁaszkiewiczJ. NowakŁ. SzydełkoT. Current methods facilitating diagnosis of upper tract urothelial carcinoma: A comprehensive literature review.Curr. Opin. Urol.202333323023810.1097/MOU.000000000000107836727755
     [Google Scholar]
  7. ZhangB. YuW. ZhouL.Q. HeZ.S. ShenC. HeQ. LiJ. LiuL.B. WangC. ChenX.Y. FanY. HuS. ZhangL. HanW.K. JinJ. Prognostic significance of preoperative albumin-globulin ratio in patients with upper tract urothelial carcinoma.PLoS One20151012e014496110.1371/journal.pone.014496126681341
     [Google Scholar]
  8. GregoryA.D. HoughtonM.A. Tumor-associated neutrophils: New targets for cancer therapy.Cancer Res.20117172411241610.1158/0008‑5472.CAN‑10‑258321427354
     [Google Scholar]
  9. TanakaN. KikuchiE. KanaoK. MatsumotoK. ShirotakeS. MiyazakiY. KobayashiH. KanekoG. HagiwaraM. IdeH. ObataJ. HoshinoK. HayakawaN. KosakaT. HaraS. OyamaM. MommaT. NakajimaY. JinzakiM. OyaM. A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio for upper tract urothelial carcinoma treated with radical nephroureterectomy.Ann. Surg. Oncol.201421124041404810.1245/s10434‑014‑3830‑324912614
     [Google Scholar]
  10. NishiharaK. SuekaneS. UedaK. NakiriM. MatsuoM. IgawaT. High postoperative neutrophil-to-lymphocyte ratio as a poor prognostic marker in patients with upper tract urothelial carcinoma.Oncol. Lett.20191765241525010.3892/ol.2019.1017831186740
     [Google Scholar]
  11. KishimotoN. TakaoT. KuribayashiS. YamamichiG. NakanoK. KawamuraM. TsutaharaK. TanigawaG. YamaguchiS. The neutrophil-to-lymphocyte ratio as a predictor of intravesical recurrence in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy.Int. J. Clin. Oncol.201722115315810.1007/s10147‑016‑1040‑727614622
     [Google Scholar]
  12. SungH.H. JeonG.H. JeongB.C. SeoS.I. JeonS.S. ChoiH.Y. LeeH.M. Clinical significance of prognosis using the neutrophil–lymphocyte ratio and erythrocyte sedimentation rate in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma.BJU Int.2015115458759410.1111/bju.1284624947340
     [Google Scholar]
  13. ZhaoZ. XieS. FengB. ZhangS. SunY. GuoH. YangR. Preoperative risk classification using neutrophil-to-lymphocyte ratio and albumin for upper tract urothelial carcinoma treated with radical nephroureterectomy.Cancer Manag. Res.2020129023903210.2147/CMAR.S27433233061597
     [Google Scholar]
  14. JanH.C. HuC.Y. YangW.H. OuC.H. Combination of platelet-lymphocyte ratio and monocyte-lymphocyte ratio as a new promising prognostic factor in upper tract urothelial carcinoma with large tumor sizes > 3 cm.Clin. Genitourin. Cancer2020184e484e50010.1016/j.clgc.2019.12.00832199741
     [Google Scholar]
  15. SonS. HwangE.C. JungS.I. KwonD.D. ChoiS.H. KwonT.G. NohJ.H. KimM.K. SeoI.Y. KimC.S. KangS.G. CheonJ. HaH.K. JeongC.W. KuJ.H. KwakC. KimH.H. Prognostic value of preoperative systemic inflammation markers in localized upper tract urothelial cell carcinoma: A large, multicenter cohort analysis.Minerva Urol. Nephrol.201870330030910.23736/S0393‑2249.18.02914‑429381018
     [Google Scholar]
  16. TillettW.S. FrancisT.Jr. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus.J. Exp. Med.193052456157110.1084/jem.52.4.56119869788
     [Google Scholar]
  17. MahmoudF.A. RiveraN.I. The role of C-reactive protein as a prognostic indicator in advanced cancer.Curr. Oncol. Rep.20024325025510.1007/s11912‑002‑0023‑111937016
     [Google Scholar]
  18. ObataJ. KikuchiE. TanakaN. MatsumotoK. HayakawaN. IdeH. MiyajimaA. NakagawaK. OyaM. C-reactive protein: A biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy.Urol. Oncol.20133181725173010.1016/j.urolonc.2012.05.00823141922
     [Google Scholar]
  19. AzizA. RinkM. GakisG. KluthL.A. DechetC. MillerF. OttoW. GierthM. DenzingerS. SchwentnerC. StenzlA. FischM. BurgerM. FritscheH.M. Preoperative C-reactive protein in the serum: A prognostic biomarker for upper urinary tract urothelial carcinoma treated with radical nephroureterectomy.Urol. Int.201493335236010.1159/00036224825138778
     [Google Scholar]
  20. SteinB. SchraderA.J. WegenerG. SeidelC. KuczykM.A. SteffensS. Preoperative serum C- reactive protein: A prognostic marker in patients with upper urinary tract urothelial carcinoma.BMC Cancer201313110110.1186/1471‑2407‑13‑10123497335
     [Google Scholar]
  21. EggerV. HuttererG.C. MischingerJ. SelesM. PichlerR. MannweilerS. HuberK. BalihodzicA. SpiegelbergJ. BauernhoferT. AhyaiS. ZigeunerR. PichlerM. BarthD.A. Preoperative fibrinogen/CRP score predicts survival in upper urothelial tract carcinoma patients undergoing radical curative surgery.World J. Urol.20234151359136410.1007/s00345‑023‑04379‑y37024555
     [Google Scholar]
  22. TanakaN. KikuchiE. KanaoK. MatsumotoK. ShirotakeS. MiyazakiY. KobayashiH. KanekoG. HagiwaraM. IdeH. ObataJ. HoshinoK. HayakawaN. KosakaT. HaraS. NakagawaK. JinzakiM. OyaM. Impact of combined use of blood-based inflammatory markers on patients with upper tract urothelial carcinoma following radical nephroureterectomy: Proposal of a cumulative marker score as a novel predictive tool for prognosis.Eur. Urol. Focus201511546310.1016/j.euf.2015.02.00128723357
     [Google Scholar]
  23. WilbrahamB.C.A. TazzymanS. MarshallJ.M. LewisC.E. Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro.Cancer Res.200060174719472410987275
     [Google Scholar]
  24. LeeS.Y. ParkL.O. SukS.H. Role of fibrinogen covalently associated with cell membrane in blood-borne lung tumor colony formation of murine mammary carcinoma cells.Oncology200059323824410.1159/00001216711053992
     [Google Scholar]
  25. LiuR. ZhouX. ZouL. ChenQ. HuY. HuJ. WuX. JiangH. Clinicopathological and prognostic significance of preoperative plasma fibrinogen level in patients with upper urinary tract urothelial carcinoma: A retrospective tumor marker prognostic study.Int. J. Surg.201965889310.1016/j.ijsu.2019.03.02230951871
     [Google Scholar]
  26. ChengY.C. HuangC.N. WuW.J. LiC.C. KeH.L. LiW.M. TuH.P. LiC.F. ChangL.L. YehH.C. The prognostic significance of inflammation-associated blood cell markers in patients with upper tract urothelial carcinoma.Ann. Surg. Oncol.201623134335110.1245/s10434‑015‑4781‑z26242371
     [Google Scholar]
  27. XuH. TanP. AiJ. HuangY. LinT. YangL. WeiQ. Prognostic impact of preoperative albumin–globulin ratio on oncologic outcomes in upper tract urothelial carcinoma treated with radical nephroureterectomy.Clin. Genitourin. Cancer2018165e1059e106810.1016/j.clgc.2018.06.00329980449
     [Google Scholar]
  28. HuangJ. WangY. YuanY. ChenY. KongW. ChenH. ZhangJ. HuangY. Preoperative serum pre-albumin as an independent prognostic indicator in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy.Oncotarget2017822367723677910.18632/oncotarget.1369427906675
     [Google Scholar]
  29. TanP. XieN. AiJ. XuH. XuH. LiuL. YangL. WeiQ. The prognostic significance of Albumin-to-Alkaline Phosphatase Ratio in upper tract urothelial carcinoma.Sci. Rep.2018811231110.1038/s41598‑018‑29833‑530120312
     [Google Scholar]
  30. SuY.C. WenS.C. LiC.C. SuH.C. KeH.L. LiW.M. LeeH.Y. LiC.Y. YangS.F. TuH.P. WuW.J. YehH.C. Low hemoglobin-to-red cell distribution width ratio is associated with disease progression and poor prognosis in upper tract urothelial carcinoma.Biomedicines20219667210.3390/biomedicines906067234208273
     [Google Scholar]
  31. FanB. HuangY. WenS. TengQ. YangX. SunM. ChenT. HuangY. WangY. LiuZ. Predictive value of preoperative positive urine cytology for development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma: A prognostic nomogram based on a retrospective multicenter cohort study and systematic meta-analysis.Front. Oncol.20211173131810.3389/fonc.2021.73131834660295
     [Google Scholar]
  32. BianchiC. DonadioC. TramontiG. ConsaniC. LorussoP. RossiG. Reappraisal of serum β2-microglobulin as marker of GFR.Ren. Fail.2001233-441942910.1081/JDI‑10010472511499557
     [Google Scholar]
  33. YokoyamaE FuruyaS KumamotoY. Clinical evaluation on quantitation of serum and urinary beta2-microglobulin, especially as an index of renal tubular function (author's transl).Nihon Hinyokika Gakkai Zasshi19776843233610.5980/jpnjurol1928.68.4_323
     [Google Scholar]
  34. HanJ.H. JeongS. KimS.H. YukH.D. JeongC.W. KwakC. KuJ.H. Increased urinary B2-microglobulin is associated with poor prognosis of upper tract urothelial carcinoma.Front. Oncol.202212100876310.3389/fonc.2022.100876336303834
     [Google Scholar]
  35. IdeH. KikuchiE. HagiwaraM. HayakawaN. HongoH. MiyajimaA. OyaM. Urinary pH levels are strongly associated with bladder recurrence after nephroureterectomy in upper tract urothelial carcinoma patients with a smoking history.Ann. Surg. Oncol.201623S51029103810.1245/s10434‑016‑5555‑y27613550
     [Google Scholar]
  36. HanJ.H. JeongS. YukH.D. JeongC.W. KwakC. KuJ.H. Acidic urine is associated with poor prognosis of upper tract urothelial carcinoma.Front. Oncol.20221181778110.3389/fonc.2021.81778135141155
     [Google Scholar]
  37. KeC. HuZ. YangC. UroVysionTM fluorescence in situ hybridization in urological cancers: A narrative review and future perspectives.Cancers20221421542310.3390/cancers1421542336358841
     [Google Scholar]
  38. GuanB. DuY. SuX. CaoZ. LiY. ZhanY. PengD. XiongG. FangD. DingY. HeS. GongY. HeQ. LiX. ZhouL. Positive urinary fluorescence in situ hybridization indicates poor prognosis in patients with upper tract urothelial carcinoma.Oncotarget2018918146521466010.18632/oncotarget.2400729581871
     [Google Scholar]
  39. ClementP.M.J. JohanssonH.E. WolffE.C. ParkM.H. Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells.FEBS J.200627361102111410.1111/j.1742‑4658.2006.05135.x16519677
     [Google Scholar]
  40. ChenW. LuoJ.H. HuaW.F. ZhouF.J. LinM.C. KungH.F. ZengY.X. GuanX.Y. XieD. Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy.Cancer Epidemiol. Biomarkers Prev.200918240040810.1158/1055‑9965.EPI‑08‑075419155439
     [Google Scholar]
  41. LuoJ.H. HuaW.F. RaoH.L. LiaoY.J. KungH.F. ZengY.X. GuanX.Y. ChenW. XieD. Overexpression of EIF-5A2 predicts tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder.Cancer Sci.2009100589690210.1111/j.1349‑7006.2009.01126.x19298601
     [Google Scholar]
  42. WeiJ-H. CaoJ-Z. ZhangD. LiaoB. ZhongW-M. LuJ. ZhaoH-W. ZhangJ-X. TongZ-T. FanS. LiangC-Z. LiaoY-B. PangJ. WuR-H. FangY. ChenZ-H. LiB. XieD. ChenW. LuoJ-H. EIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo.Br. J. Cancer201411071767177710.1038/bjc.2014.5224504366
     [Google Scholar]
  43. FangY. CenJ.J. CaoJ.Z. HuangY. FengZ.H. LuJ. WeiJ.H. ChenZ.H. LiangY.P. LiaoB. LuoJ.H. ChenW. Overexpression of EIF5A2 in upper urinary tract urothelial carcinoma is a new independent prognostic marker of survival.Future Oncol.201915172009201810.2217/fon‑2018‑074830931608
     [Google Scholar]
  44. HuangY. WeiJ. FangY. ChenZ. CenJ. FengZ. LuJ. LiangY. LuoJ. ChenW. Prognostic value of AIB1 and EIF5A2 in intravesical recurrence after surgery for upper tract urothelial carcinoma.Cancer Manag. Res.2018106997701110.2147/CMAR.S18539230588104
     [Google Scholar]
  45. HuangY. CenJ. WeiJ. ChenZ. FangY. FengZ. LuJ. LiangY. LuoJ. MoC. ChenW. Impact of AIB1 expression on the prognosis of upper tract urothelial carcinoma after radical nephroureterectomy.Cancer Biomark.201925215116010.3233/CBM‑18202031045512
     [Google Scholar]
  46. AvetaA. CilioS. ContieriR. SpenaG. NapolitanoL. ManfrediC. FrancoA. CrocerossaF. CerratoC. FerroM. GiudiceD.F. VerzeP. LasorsaF. SaloniaA. NairR. WalzJ. LucarelliG. PandolfoS.D. Urinary microRNAs as biomarkers of urological cancers: A systematic review.Int. J. Mol. Sci.202324131084610.3390/ijms24131084637446024
     [Google Scholar]
  47. IzquierdoL. TorresI.M. MallofréC. LozanoJ.J. CrinquetteV.M. LeroyX. ColinP. ComperatE. RoupretM. AlcarazA. MengualL. Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma.BJU Int.2014113581382110.1111/bju.1255124180461
     [Google Scholar]
  48. IzquierdoL. MontalboR. TorresI.M. MallofréC. BackhausR.M. RubioJ. Van der HeijdenA.G. SchaafsmaE. BeltranL.A. BlancaA. LawrentschukN. AlcarazA. MengualL. Prognostic microRNAs in upper tract urothelial carcinoma: Multicenter and international validation study.Oncotarget2017831515225152910.18632/oncotarget.1788428881664
     [Google Scholar]
  49. RobertsS.A. LawrenceM.S. KlimczakL.J. GrimmS.A. FargoD. StojanovP. KiezunA. KryukovG.V. CarterS.L. SaksenaG. HarrisS. ShahR.R. ResnickM.A. GetzG. GordeninD.A. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.Nat. Genet.201345997097610.1038/ng.270223852170
     [Google Scholar]
  50. MiddlebrooksC.D. BandayA.R. MatsudaK. UdquimK.I. OnabajoO.O. PaquinA. FigueroaJ.D. ZhuB. KoutrosS. KuboM. ShuinT. FreedmanN.D. KogevinasM. MalatsN. ChanockS.J. ClosasG.M. SilvermanD.T. RothmanN. OlssonP.L. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.Nat. Genet.201648111330133810.1038/ng.367027643540
     [Google Scholar]
  51. DuensingS. LeeL.Y. DuensingA. BasileJ. PiboonniyomS. GonzalezS. CrumC.P. MüngerK. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle.Proc. Natl. Acad. Sci.20009718100021000710.1073/pnas.17009329710944189
     [Google Scholar]
  52. PetljakM. AlexandrovL.B. BrammeldJ.S. PriceS. WedgeD.C. GrossmannS. DawsonK.J. JuY.S. IorioF. TubioJ.M.C. KohC.C. SoaresG.I. MartínR.B. OtluB. O’MearaS. ButlerA.P. MenziesA. BhosleS.G. RaineK. JonesD.R. TeagueJ.W. BealK. LatimerC. O’NeillL. ZamoraJ. AndersonE. PatelN. MaddisonM. NgB.L. GrahamJ. GarnettM.J. McDermottU. ZainalN.S. CampbellP.J. StrattonM.R. Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis.Cell2019176612821294.e2010.1016/j.cell.2019.02.01230849372
     [Google Scholar]
  53. MossT.J. QiY. XiL. PengB. KimT.B. EzzedineN.E. MosquedaM.E. GuoC.C. CzerniakB.A. IttmannM. WheelerD.A. LernerS.P. MatinS.F. Comprehensive genomic characterization of upper tract urothelial carcinoma.Eur. Urol.201772464164910.1016/j.eururo.2017.05.04828601352
     [Google Scholar]
  54. HeL. YangB. JianD. LuoH. WangD. DaiN. Prognostic value of HPV E6 and APOBEC3B in upper urinary tract urothelial carcinoma.Dis. Markers202220221910.1155/2022/214749435903294
     [Google Scholar]
  55. NakamuraN. RamaswamyS. VazquezF. SignorettiS. LodaM. SellersW.R. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN.Mol. Cell. Biol.200020238969898210.1128/MCB.20.23.8969‑8982.200011073996
     [Google Scholar]
  56. de BrachèneC.A. DemoulinJ.B. FOXO transcription factors in cancer development and therapy.Cell. Mol. Life Sci.20167361159117210.1007/s00018‑015‑2112‑y26686861
     [Google Scholar]
  57. MiyamotoH. ZhengY. IzumiK. Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma.Curr. Canc. Drug Targ.2012121142210.2174/15680091279888896522111835
     [Google Scholar]
  58. HsuI. VitkusS. DaJ. YehS. Role of oestrogen receptors in bladder cancer development.Nat. Rev. Urol.201310631732610.1038/nrurol.2013.5323588401
     [Google Scholar]
  59. InoueS. MizushimaT. MiyamotoH. Role of the androgen receptor in urothelial cancer.Mol. Cell. Endocrinol.2018465738110.1016/j.mce.2017.06.02128652170
     [Google Scholar]
  60. IdeH. JiangG. MizushimaT. FujitaK. InoueS. YamaguchiS. FushimiH. NonomuraN. MiyamotoH. Forkhead box O1 as an indicator of prognosis is inactivated in urothelial carcinoma of the upper urinary tract.Oncol. Lett.201817148248710.3892/ol.2018.951030655790
     [Google Scholar]
  61. KanapathipillaiM. Treating p53 mutant aggregation-associated cancer.Cancers201810615410.3390/cancers1006015429789497
     [Google Scholar]
  62. LeeJ.Y. ChoK.S. DiazR.R. ChoiY.D. ChoiH.Y. p53 expression as a prognostic factor in upper urinary tract urothelial carcinoma: A systematic review and meta-analysis.Urol. Int.2015941505710.1159/00036022725171290
     [Google Scholar]
  63. KrabbeL.M. BagrodiaA. HaddadA.Q. KapurP. KhalilD. HynanL.S. WoodC.G. KaramJ.A. WeizerA.Z. RamanJ.D. RemziM. LeclercqR.N. HaitelA. RoscignoM. BolenzC. BensalahK. SagalowskyA.I. ShariatS.F. LotanY. MargulisV. Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract.J. Urol.201519351486149310.1016/j.juro.2014.11.00725451830
     [Google Scholar]
  64. ChenC.H. TsaiM.Y. ChiangP.C. SungM.T. LuoH.L. SuenJ.L. TsaiE.M. ChiangP.H. Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma.Cancer Immunol. Immunother.202170102981299010.1007/s00262‑021‑02890‑y33740124
     [Google Scholar]
  65. MiyaiK. KawamuraK. ItoK. MatsukumaS. TsudaH. Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma.BMC Cancer202222178710.1186/s12885‑022‑09893‑735850759
     [Google Scholar]
  66. SzarvasT. BeckerM. DorpV.F. GethmannC. TötschM. BánkfalviÁ. SchmidK.W. RomicsI. RübbenH. ErgünS. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer.Cancer Sci.201010151300130810.1111/j.1349‑7006.2010.01506.x20180812
     [Google Scholar]
  67. KovácsP.T. MayerT. CsizmarikA. VáradiM. OláhC. SzélesÁ. TschirdewahnS. KrafftU. HadaschikB. NyirádyP. RieszP. SzarvasT. Elevated pre-treatment serum MMP-7 levels are associated with the presence of metastasis and poor survival in upper tract urothelial carcinoma.Biomedicines202210369810.3390/biomedicines1003069835327500
     [Google Scholar]
  68. SuzukiK. ZhuB. RittlingS.R. DenhardtD.T. GoldbergH.A. MccullochC.A.G. SodekJ. Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts.J. Bone Miner. Res.20021781486149710.1359/jbmr.2002.17.8.148612162503
     [Google Scholar]
  69. KeH.L. ChangL.L. YangS.F. LinH.H. LiC.C. WuD.C. WuW.J. Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma.Urol. Oncol.201129670370910.1016/j.urolonc.2009.10.00920022267
     [Google Scholar]
  70. LiY. HeS. HeA. GuanB. GeG. ZhanY. WuY. GongY. PengD. BaoZ. LiX. ZhouL. Identification of plasma secreted phosphoprotein 1 as a novel biomarker for upper tract urothelial carcinomas.Biomed. Pharmacother.201911310874410.1016/j.biopha.2019.10874430844659
     [Google Scholar]
  71. HondaK. YamadaT. EndoR. InoY. GotohM. TsudaH. YamadaY. ChibaH. HirohashiS. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion.J. Cell Biol.199814061383139310.1083/jcb.140.6.13839508771
     [Google Scholar]
  72. HondaK. Development of biomarkers to predict recurrence by determining the metastatic ability of cancer cells.J. Nippon Med. Sch.2022891243210.1272/jnms.JNMS.2022_89‑11834526453
     [Google Scholar]
  73. GrigoreA. JollyM. JiaD. CarsonF.M. LevineH. Tumor budding: The name is EMT. Partial EMT.J. Clin. Med.2016555110.3390/jcm505005127136592
     [Google Scholar]
  74. TentlerD. LomertE. NovitskayaK. BarlevN.A. Role of ACTN4 in tumorigenesis, metastasis, and EMT.Cells2019811142710.3390/cells811142731766144
     [Google Scholar]
  75. HondaK. YamadaT. HayashidaY. IdogawaM. SatoS. HasegawaF. InoY. OnoM. HirohashiS. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer.Gastroenterology20051281516210.1053/j.gastro.2004.10.00415633123
     [Google Scholar]
  76. FukumotoM. KurisuS. YamadaT. TakenawaT. α-Actinin-4 enhances colorectal cancer cell invasion by suppressing focal adhesion maturation.PLoS One2015104e012061610.1371/journal.pone.012061625860875
     [Google Scholar]
  77. ProcházkováI. LenčoJ. FučíkováA. DreslerJ. ČápkováL. HrstkaR. NenutilR. BouchalP. Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness.Biochim. Biophys. Acta. Proteins Proteomics20171865548849810.1016/j.bbapap.2017.02.01228216224
     [Google Scholar]
  78. FangC. LiJ.J. DengT. LiB.H. GengP.L. ZengX.T. Actinin-4 as a diagnostic biomarker in serum of breast cancer patients.Med. Sci. Monit.2019253298330210.12659/MSM.91240431054253
     [Google Scholar]
  79. YamagataN. ShyrY. YanagisawaK. EdgertonM. DangT.P. GonzalezA. NadafS. LarsenP. RobertsJ.R. NesbittJ.C. JensenR. LevyS. MooreJ.H. MinnaJ.D. CarboneD.P. A training-testing approach to the molecular classification of resected non-small cell lung cancer.Clin. Cancer Res.20039134695470414581339
     [Google Scholar]
  80. WangM.C. ChangY.H. WuC.C. TyanY.C. ChangH.C. GoanY.G. LaiW.W. ChengP.N. LiaoP.C. Alpha-actinin 4 is associated with cancer cell motility and is a potential biomarker in non-small cell lung cancer.J. Thorac. Oncol.201510228630110.1097/JTO.000000000000039625299231
     [Google Scholar]
  81. NoroR. HondaK. TsutaK. IshiiG. MaeshimaA.M. MiuraN. FurutaK. ShibataT. TsudaH. OchiaiA. SakumaT. NishijimaN. GemmaA. AsamuraH. NagaiK. YamadaT. Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification.Ann. Oncol.201324102594260010.1093/annonc/mdt29323899839
     [Google Scholar]
  82. NoroR. IshigameT. WalshN. ShiraishiK. RoblesA.I. RyanB.M. SchetterA.J. BowmanE.D. WelshJ.A. SeikeM. GemmaA. SkaugV. MollerupS. HaugenA. YokotaJ. KohnoT. HarrisC.C. A two-gene prognostic classifier for early-stage lung squamous cell carcinoma in multiple large-scale and geographically diverse cohorts.J. Thorac. Oncol.2017121657610.1016/j.jtho.2016.08.14127613525
     [Google Scholar]
  83. KikuchiS. HondaK. TsudaH. HiraokaN. ImotoI. KosugeT. UmakiT. OnozatoK. ShitashigeM. YamaguchiU. OnoM. TsuchidaA. AokiT. InazawaJ. HirohashiS. YamadaT. Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas.Clin. Cancer Res.200814175348535610.1158/1078‑0432.CCR‑08‑007518765526
     [Google Scholar]
  84. ShojiH. MiuraN. UenoH. HondaK. Measurement of copy number of ACTN4 to optimize the therapeutic strategy for locally advanced pancreatic cancer.Pancreatology201818662462910.1016/j.pan.2018.06.00329921500
     [Google Scholar]
  85. YamamotoS. TsudaH. HondaK. KitaT. TakanoM. TamaiS. InazawaJ. YamadaT. MatsubaraO. Actinin-4 expression in ovarian cancer: A novel prognostic indicator independent of clinical stage and histological type.Mod. Pathol.200720121278128510.1038/modpathol.380096617873890
     [Google Scholar]
  86. YamamotoS. TsudaH. HondaK. OnozatoK. TakanoM. TamaiS. ImotoI. InazawaJ. YamadaT. MatsubaraO. Actinin-4 gene amplification in ovarian cancer: A candidate oncogene associated with poor patient prognosis and tumor chemoresistance.Mod. Pathol.200922449950710.1038/modpathol.2008.23419151661
     [Google Scholar]
  87. YamamotoS. TsudaH. HondaK. TakanoM. TamaiS. ImotoI. InazawaJ. YamadaT. MatsubaraO. ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas.Histopathology20126071073108310.1111/j.1365‑2559.2011.04163.x22348389
     [Google Scholar]
  88. WatabeY. MoriT. YoshimotoS. NomuraT. ShibaharaT. YamadaT. HondaK. Copy number increase of ACTN4 is a prognostic indicator in salivary gland carcinoma.Cancer Med.20143361362210.1002/cam4.21424574362
     [Google Scholar]
  89. KakuyaT. MoriT. YoshimotoS. WatabeY. MiuraN. ShojiH. OnidaniK. ShibaharaT. HondaK. Prognostic significance of gene amplification of ACTN4 in stage I and II oral tongue cancer.Int. J. Oral Maxillofac. Surg.201746896897610.1016/j.ijom.2017.03.00128385383
     [Google Scholar]
  90. IshizuyaY. UemuraM. NarumiR. TomiyamaE. KohY. MatsushitaM. NakanoK. HayashiY. WangC. KatoT. HatanoK. KawashimaA. UjikeT. FujitaK. ImamuraR. AdachiJ. TomonagaT. NonomuraN. The role of actinin-4 (ACTN4) in exosomes as a potential novel therapeutic target in castration-resistant prostate cancer.Biochem. Biophys. Res. Commun.2020523358859410.1016/j.bbrc.2019.12.08431941606
     [Google Scholar]
  91. KoizumiT. NakatsujiH. FukawaT. AvirmedS. FukumoriT. TakahashiM. KanayamaH. The role of actinin-4 in bladder cancer invasion.Urology201075235736410.1016/j.urology.2009.09.03719969329
     [Google Scholar]
  92. YoshiiH. ItoK. AsanoT. HoriguchiA. HayakawaM. AsanoT. Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer.Oncol. Rep.20133031073108010.3892/or.2013.257723817592
     [Google Scholar]
  93. KawamuraK. MiyaiK. SatoK. MatsukumaS. HondaK. ItoK. TsudaH. Copy number gain of ACTN4 is associated with poor prognosis in patients with upper urinary tract urothelial carcinoma.Cancer Sci.202311483411342210.1111/cas.1584137226638
     [Google Scholar]
  94. KimH.S. LeeH.S. KuJ.H. Prognostic impact of postoperative neutrophil-to-lymphocyte ratio on survival outcomes of patients treated with radical nephroureterectomy for upper urinary tract urothelial carcinoma: A single institution retrospective analysis using propensity score matching.J. Cancer20231471174118110.7150/jca.7697737215445
     [Google Scholar]
  95. GhoraiR.P. NayakB. GoelR. GuptaP. RajR. KaushalS. NayyarR. KumarR. SethA. The prognostic role of preoperative neutrophil-to-lymphocyte ratio in upper tract urothelial carcinoma.Indian J. Urol.202440319119610.4103/iju.iju_22_2439100608
     [Google Scholar]
  96. SaitoS. TakahashiH. YataY. TakamizawaS. HaraS. MiyajimaK. IwataniK. YasueK. NishikawaH. YamamotoT. KoideH. SadakaneI. AtsutaM. MoriK. ImaiY. KayanoS. MurakamiM. TashiroK. TsuzukiS. YamadaH. MikiJ. UrabeF. KimuraT. Associations between early changes in the neutrophil-to- lymphocyte ratio after radical nephroureterectomy and treatment outcomes.Jpn. J. Clin. Oncol.202454111201120710.1093/jjco/hyae08138920339
     [Google Scholar]
  97. CaoZ.P. GuanB. ZhaoG.Z. FangD. XiongG.Y. LiX.S. ZhouL.Q. Validation of the pretreatment neutrophil-to-lymphocyte ratio as a prognostic factor in a large cohort of chinese patients with upper tract urothelial carcinoma.Chin. Med. J.2017130172063206810.4103/0366‑6999.21341428836549
     [Google Scholar]
  98. HashimotoM. FujitaK. NakayamaT. FujimotoS. HamaguchiM. NishimotoM. KikuchiT. AdomiS. BannoE. VelascoD.M.A. SaitoY. ShimizuN. MoriY. MinamiT. NozawaM. NoseK. YoshimuraK. UemuraH. Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patients.Transl. Androl. Urol.20211072838284710.21037/tau‑21‑18534430386
     [Google Scholar]
  99. TeishimaJ. HirataJ. TogeT. UematsuR. MitaY. YoshiiT. NakamuraI. Prognostic model using postoperative normalization of C-reactive protein levels in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.Can. Urol. Assoc. J.2023183E84E9010.5489/cuaj.839338507711
     [Google Scholar]
  100. YangL. WeiQ. XuH. AiJ-Z. TanP. LinT-H. JinX. GongL-N. LeiH-R. Pretreatment elevated fibrinogen level predicts worse oncologic outcomes in upper tract urothelial carcinoma.Asian J. Androl.202022217718310.4103/aja.aja_38_1931169138
     [Google Scholar]
  101. KurodaK. TasakiS. AsakumaJ. HoriguchiA. ItoK. Preoperative risk stratification using plasma fibrinogen levels can predict lymphovascular invasion and poor prognosis in patients with upper urinary tract urothelial carcinoma.Mol. Clin. Oncol.202114510210.3892/mco.2021.226433796291
     [Google Scholar]
  102. OtsukaM. KamasakoT. UemuraT. TakeshitaN. ShinozakiT. KobayashiM. KomaruA. FukasawaS. Prognostic role of the preoperative serum albumin : Globulin ratio after radical nephroureterectomy for upper tract urothelial carcinoma.Int. J. Urol.2018251087187810.1111/iju.1376730103271
     [Google Scholar]
  103. KuJ.H. KimM. ChoiW.S. KwakC. KimH.H. Preoperative serum albumin as a prognostic factor in patients with upper urinary tract urothelial carcinoma.Int. Braz. J. Urol.201440675376210.1590/S1677‑5538.IBJU.2014.06.0625615244
     [Google Scholar]
  104. AalamiA.H. AalamiF. Diagnostic performance of fluorescence in situ hybridization (FISH) in upper tract urothelial carcinoma (UTUC): A systematic review and meta-analysis.Int. J. Clin. Oncol.202227101605161510.1007/s10147‑022‑02216‑735856125
     [Google Scholar]
  105. EismannL. MummJ.N. BohnL. WülfingC. ClarkeK.R. CasuscelliJ. WaidelichR. StiefC.G. SchlenkerB. RodlerS. The impact of fluorescence in situ hybridization on the staging of upper tract urothelial carcinoma.Urol. Int.20211057-863163610.1159/00051345933582671
     [Google Scholar]
  106. GomellaL.G. MannM.J. ClearyR.C. HuboskyS.G. BagleyD.H. ThumarA.B. McCueP.A. LallasC.D. TrabulsiE.J. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: The largest single-institution experience to date.Can. J. Urol.20172418620862628263126
     [Google Scholar]
  107. SuX. HaoH. LiX. HeZ. GongK. ZhangC. CaiL. ZhangQ. YaoL. DingY. GongY. FangD. ZhangZ. ZhouL. Fluorescence in situ hybridization status of voided urine predicts invasive and high-grade upper tract urothelial carcinoma.Oncotarget2017816261062611110.18632/oncotarget.1534428212539
     [Google Scholar]
  108. JinH. LinT. HaoJ. QiuS. XuH. YuR. SunS. ZhangP. LiuZ. YangL. LiuL. HanP. WeiQ. A comprehensive comparison of fluorescence in situ hybridization and cytology for the detection of upper urinary tract urothelial carcinoma.Medicine20189752e1385910.1097/MD.000000000001385930593189
     [Google Scholar]
  109. YuQ. LiY. LiG. LiT. ZengH. YangZ. WangD. Prospective evaluation of FISH for detecting upper tract urothelial carcinoma in voided urine specimens.Oncol. Lett.201612118318810.3892/ol.2016.459227347122
     [Google Scholar]
  110. TangF. WangX. LiuT. WangH. WanZ. FuQ. ZhengZ. AersiM. PengJ. Multiple fluorescences in situ hybridization status in excreted urine improve diagnostic efficacy for upper urinary tract urothelial carcinomas.Urol. J.202421210711310.22037/uj.v20i.797338168059
     [Google Scholar]
  111. SzélesÁ. KovácsP.T. CsizmarikA. VáradiM. RieszP. FazekasT. VáncsaS. HegyiP. OláhC. TschirdewahnS. DarrC. KrafftU. GrünwaldV. HadaschikB. HorváthO. NyirádyP. SzarvasT. High pretreatment serum PD-L1 levels are associated with muscle invasion and shorter survival in upper tract urothelial carcinoma.Biomedicines20221010256010.3390/biomedicines1010256036289821
     [Google Scholar]
  112. WardM. AlbertsonD. FurtadoL.V. DeftereosG. PD-L1 tumor cell expression in upper tract urothelial carcinomas is associated with higher pathologic stage.Appl. Immunohistochem. Mol. Morphol.2022301566110.1097/PAI.000000000000095734183505
     [Google Scholar]
  113. LuY. KangJ. LuoZ. SongY. TianJ. LiZ. WangX. LiuL. YangY. LiuX. The prevalence and prognostic role of PD-L1 in upper tract urothelial carcinoma patients underwent radical nephroureterectomy: A systematic review and meta-analysis.Front. Oncol.202010140010.3389/fonc.2020.0140032974145
     [Google Scholar]
  114. MiyamaY. MorikawaT. MiyakawaJ. KoyamaY. KawaiT. KumeH. FukayamaM. The prognostic value of PD-L1 expression in upper tract urothelial carcinoma varies according to platelet count.Cancer Med.2018794330433810.1002/cam4.168630062756
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673339558250123110322
Loading
New Advancements in Prognostic Biomarkers for Upper Tract Urothelial Carcinoma
Curr. Med. Chem. 33, 586 (2026); https://doi.org/10.2174/0109298673339558250123110322
/content/journals/cmc/10.2174/0109298673339558250123110322
/content/journals/cmc/10.2174/0109298673339558250123110322
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Biomarkers; bladder cancer; epithelial tumor; prognosis; renal pelvis; upper tract urothelial carcinoma

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test